Trader consensus implies a 91.5% probability of no hantavirus vaccine approval in 2026, driven by the absence of any Phase 3 clinical trials or regulatory submissions to FDA, EMA, or WHO as of May 2026. Official CDC and WHO data confirm no licensed vaccines exist for North American hantaviruses causing hantavirus pulmonary syndrome (HPS), with global cases remaining rare—under 900 U.S. reports since 1993—limiting commercial incentives despite early-phase DNA vaccine progress (e.g., Phase 1/2 trials for Hantaan and Andes strains). Recent structural mapping of hantavirus proteins in March 2026 offers preclinical promise but cannot accelerate timelines exceeding 2–3 years for Phase 3 and review. A major outbreak, like the ongoing multi-country cruise ship cluster, or breakthrough mRNA platform could spur fast-tracking, though epidemiological baselines and trial recruitment challenges make this unlikely. Monitor FDA calendars and clinicaltrials.gov for shifts.
Experimental AI-generated summary referencing Polymarket data. This is not trading advice and plays no role in how this market resolves. · UpdatedHantavirus vaccine in 2026?
Hantavirus vaccine in 2026?
$18,791 Vol.
$18,791 Vol.
Dec 31, 2026
$18,791 Vol.
$18,791 Vol.
Dec 31, 2026
This market will resolve to "Yes" if any vaccine intended for humans and inoculating against Hantavirus (including Hantavirus Pulmonary Syndrome (HPS) or Hemorrhagic Fever with Renal Syndrome (HFRS)) receives full approval from the U.S. Food and Drug Administration between market creation and December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the FDA, including its list of approved vaccines (https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states), however a consensus of credible reporting may also be used.Trader consensus implies a 91.5% probability of no hantavirus vaccine approval in 2026, driven by the absence of any Phase 3 clinical trials or regulatory submissions to FDA, EMA, or WHO as of May 2026. Official CDC and WHO data confirm no licensed vaccines exist for North American hantaviruses causing hantavirus pulmonary syndrome (HPS), with global cases remaining rare—under 900 U.S. reports since 1993—limiting commercial incentives despite early-phase DNA vaccine progress (e.g., Phase 1/2 trials for Hantaan and Andes strains). Recent structural mapping of hantavirus proteins in March 2026 offers preclinical promise but cannot accelerate timelines exceeding 2–3 years for Phase 3 and review. A major outbreak, like the ongoing multi-country cruise ship cluster, or breakthrough mRNA platform could spur fast-tracking, though epidemiological baselines and trial recruitment challenges make this unlikely. Monitor FDA calendars and clinicaltrials.gov for shifts.
This market will resolve to "Yes" if any vaccine intended for humans and inoculating against Hantavirus (including Hantavirus Pulmonary Syndrome (HPS) or Hemorrhagic Fever with Renal Syndrome (HFRS)) receives full approval from the U.S. Food and Drug Administration between market creation and December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the FDA, including its list of approved vaccines (https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states), however a consensus of credible reporting may also be used.
The primary resolution source for this market will be official information from the FDA, including its list of approved vaccines (https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states), however a consensus of credible reporting may also be used.
Market Opened: May 4, 2026, 10:39 AM ET
Volume
$18,791End Date
Dec 31, 2026Market Opened
May 4, 2026, 10:39 AM ETResolver
0x65070BE91...This market will resolve to "Yes" if any vaccine intended for humans and inoculating against Hantavirus (including Hantavirus Pulmonary Syndrome (HPS) or Hemorrhagic Fever with Renal Syndrome (HFRS)) receives full approval from the U.S. Food and Drug Administration between market creation and December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the FDA, including its list of approved vaccines (https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states), however a consensus of credible reporting may also be used.Trader consensus implies a 91.5% probability of no hantavirus vaccine approval in 2026, driven by the absence of any Phase 3 clinical trials or regulatory submissions to FDA, EMA, or WHO as of May 2026. Official CDC and WHO data confirm no licensed vaccines exist for North American hantaviruses causing hantavirus pulmonary syndrome (HPS), with global cases remaining rare—under 900 U.S. reports since 1993—limiting commercial incentives despite early-phase DNA vaccine progress (e.g., Phase 1/2 trials for Hantaan and Andes strains). Recent structural mapping of hantavirus proteins in March 2026 offers preclinical promise but cannot accelerate timelines exceeding 2–3 years for Phase 3 and review. A major outbreak, like the ongoing multi-country cruise ship cluster, or breakthrough mRNA platform could spur fast-tracking, though epidemiological baselines and trial recruitment challenges make this unlikely. Monitor FDA calendars and clinicaltrials.gov for shifts.
This market will resolve to "Yes" if any vaccine intended for humans and inoculating against Hantavirus (including Hantavirus Pulmonary Syndrome (HPS) or Hemorrhagic Fever with Renal Syndrome (HFRS)) receives full approval from the U.S. Food and Drug Administration between market creation and December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the FDA, including its list of approved vaccines (https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states), however a consensus of credible reporting may also be used.
The primary resolution source for this market will be official information from the FDA, including its list of approved vaccines (https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states), however a consensus of credible reporting may also be used.
Volume
$18,791End Date
Dec 31, 2026Market Opened
May 4, 2026, 10:39 AM ETResolver
0x65070BE91...Trader consensus implies a 91.5% probability of no hantavirus vaccine approval in 2026, driven by the absence of any Phase 3 clinical trials or regulatory submissions to FDA, EMA, or WHO as of May 2026. Official CDC and WHO data confirm no licensed vaccines exist for North American hantaviruses causing hantavirus pulmonary syndrome (HPS), with global cases remaining rare—under 900 U.S. reports since 1993—limiting commercial incentives despite early-phase DNA vaccine progress (e.g., Phase 1/2 trials for Hantaan and Andes strains). Recent structural mapping of hantavirus proteins in March 2026 offers preclinical promise but cannot accelerate timelines exceeding 2–3 years for Phase 3 and review. A major outbreak, like the ongoing multi-country cruise ship cluster, or breakthrough mRNA platform could spur fast-tracking, though epidemiological baselines and trial recruitment challenges make this unlikely. Monitor FDA calendars and clinicaltrials.gov for shifts.
Experimental AI-generated summary referencing Polymarket data. This is not trading advice and plays no role in how this market resolves. · Updated
Beware of external links.
Beware of external links.
Frequently Asked Questions